Full Year 2021 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to Q4 FY '21 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Ravi Agrawal. Thank you, and over to you, sir.
Yes. Thank you, moderator. Good morning, everyone, and a warm welcome to the Q4 FY '21 Results Conference Call of Glenmark Pharmaceuticals Limited.
Before we start the call, a review of the operations of the company. For the fourth quarter of FY 2021, Glenmark's consolidated revenue was at INR 28,599 million, recording an increase of 3.3% year-on-year. For the year ending March 31, 2021, Glenmark's consolidated revenue was at INR 109,439 million, recording an increase of 2.8% year-on-year.
Our corporate announcement. Glenmark Life Sciences Limited has filed a DRHP with the Securities and Exchange Board of India for a proposed IPO comprising a fresh issue of up to INR 11,600 million and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |